This study aimed to compare the short-term outcomes and safety profiles of androgen-deprivation therapy (ADT)+abiraterone/prednisone with those of ADT+docetaxel in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC).
A web-based database system was established to collect prospective cohort data for patients with mHSPC in Korea. From May 2019 to November 2022, 928 patients with mHSPC from 15 institutions were enrolled. Among these patients, data from 122 patients who received ADT+abiraterone/prednisone or ADT+docetaxel as the primary systemic treatment for mHSPC were collected. The patients were divided into two groups: ADT+abiraterone/prednisone group (n=102) and ADT+docetaxel group (n=20). We compared the demographic characteristics, medical histories, baseline cancer status, initial laboratory tests, metastatic burden, oncological outcomes for mHSPC, progression after mHSPC treatment, adverse effects, follow-up, and survival data between the two groups.
No significant differences in the demographic characteristics, medical histories, metastatic burden, and baseline cancer status were observed between the two groups. The ADT+abiraterone/prednisone group had a lower prostate-specific antigen (PSA) progression rate (7.8% vs. 30.0%; p=0.011) and lower systemic treatment discontinuation rate (22.5% vs. 45.0%; p=0.037). No significant differences in adverse effects, oncological outcomes, and total follow-up period were observed between the two groups.
ADT+abiraterone/prednisone had lower PSA progression and systemic treatment discontinuation rates than ADT+docetaxel. In conclusion, further studies involving larger, double-blinded randomized trials with extended follow-up periods are necessary.
The world journal of men's health. 2024 Jan 02 [Epub ahead of print]
Dong Jin Park, Tae Gyun Kwon, Jae Young Park, Jae Young Joung, Hong Koo Ha, Seong Soo Jeon, Sung-Hoo Hong, Sungchan Park, Seung Hwan Lee, Jin Seon Cho, Sung-Woo Park, Se Yun Kwon, Jung Ki Jo, Hong Seok Park, Sang-Cheol Lee, Dong Deuk Kwon, Sun Il Kim, Sang Hyun Park, Soodong Kim, Chang Wook Jeong, Cheol Kwak, Seock Hwan Choi, Korean Urologic Oncology Society Prostate Cancer Group
Department of Urology, Dongguk University College of Medicine, Gyeongju, Korea., Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea., Department of Urology, Korea University Ansan Hospital, Ansan, Korea., Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea., Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea., Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea., Department of Urology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea., Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea., Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea., Department of Urology, College of Medicine, Hanyang University, Seoul, Korea., Department of Urology, Korea University College of Medicine, Seoul, Korea., Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea., Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea., Department of Urology, Ajou University School of Medicine, Suwon, Korea., Department of Urology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea., Department of Urology, Dong-A University College of Medicine, Busan, Korea., Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea., Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea. .